ABCL
AbCellera Biologics Inc.
NASDAQ · Healthcare · Biotechnology · CA
$11.43
−1.21%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 66.2M | 75.1M | 28.8M | 38.0M | 485.4M |
| Cost of Revenue | 16.6M | 28.8M | — | — | 66.4M |
| Gross Profit | 49.6M | 46.3M | 28.8M | 38.0M | 419.0M |
| Operating Expenses | |||||
| R&D Expense | 197.8M | 186.8M | 167.3M | 175.7M | 107.9M |
| SG&A Expense | 64.7M | 76.6M | 85.5M | 75.2M | 66.8M |
| General & Admin Expense | 22.1M | — | 72.7M | 61.0M | 55.5M |
| Selling & Marketing Expense | 2.9M | — | 12.8M | 14.2M | 11.3M |
| Other Expenses | 12.2M | — | 90.8M | 24.4M | 27.8M |
| Total Operating Expenses | 274.8M | 263.4M | 343.6M | 275.2M | 202.5M |
| Cost and Expenses | 291.3M | 292.2M | 343.6M | 275.2M | 268.9M |
| Operating Income (EBIT) | (225.2M) | (217.1M) | (314.8M) | (237.2M) | 216.5M |
| Non-Operating | |||||
| Interest Income | 16.3M | 28.3M | 38.5M | 42.2M | 16.1M |
| Interest Expense | — | — | — | — | 4.0M |
| Net Interest Income | 16.3M | 28.3M | 38.5M | 42.2M | 12.0M |
| Other Non-Op Income/Expense | 28.4M | 39.5M | 114.4M | 63.2M | 22.6M |
| Non-Operating Income (excl Interest) | (23.6M) | (39.5M) | (13.6M) | (14.2M) | (10.6M) |
| EBT (Pre-Tax Income) | (196.8M) | (177.6M) | (200.4M) | (174.0M) | 239.1M |
| Income Tax Expense | (32.1M) | (31.2M) | (37.5M) | (27.6M) | 80.6M |
| Bottom Line | |||||
| Net Income | (164.7M) | (146.4M) | (162.9M) | (146.4M) | 158.5M |
| Earnings from Cont. Ops | (164.7M) | (146.4M) | (162.9M) | (146.4M) | 158.5M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (164.7M) | (146.4M) | (162.9M) | (146.4M) | 158.5M |
| Per Share | |||||
| Basic EPS | ($0.54) | ($0.49) | ($0.55) | ($0.51) | $0.56 |
| Diluted EPS | ($0.54) | ($0.49) | ($0.55) | ($0.51) | $0.50 |
| Revenue Per Share | $0.22 | $0.25 | $0.10 | $0.13 | $1.70 |
| Shares | |||||
| Basic Shares Outstanding | 305.6M | 298.7M | 294.3M | 289.2M | 285.1M |
| Diluted Shares Outstanding | 305.6M | 298.7M | 294.3M | 289.2M | 314.8M |
| Profitability Metrics | |||||
| EBITDA | (160.3M) | (148.8M) | (204.1M) | (192.2M) | 260.2M |
| D&A | 41.2M | 28.8M | 97.0M | 30.9M | 33.1M |
| EBIT | (201.6M) | (177.6M) | (301.1M) | (223.1M) | 227.1M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026